Serum Metalloprotease 3 (MMP-3) biomarker of therapeutic efficacy during treatment of rheumatoid arthritis

J Biol Regul Homeost Agents. 2021 May-Jun;35(3):1041-1045. doi: 10.23812/21-86-L.

Authors

G Di Spigna^#¹, F W Rossi^#^{1

2}, I Mormile¹, P Ladogana¹, L Buonavolontà¹, B Covelli¹, S Salzano³, F Napolitano¹, A Giannini¹, L Postiglione^{1

2}

Affiliations

¹ Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
² Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.
³ Institute of Experimental Endocrinology and Oncology "G. Salvatore" (National Research Council), Naples, Italy.

^# Contributed equally.

PMID: 34121372
DOI: 10.23812/21-86-L

No abstract available

Keywords: DMARDs; MMP-3; biomarker; methotrexate; rheumatoid arthritis.

Publication types

Letter

MeSH terms

Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Biomarkers
Drug Therapy, Combination
Humans
Matrix Metalloproteinase 3* / blood
Treatment Outcome

Substances

Antirheumatic Agents
Biomarkers
MMP3 protein, human
Matrix Metalloproteinase 3